🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06755086
Starting soon Observational

TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors

NCT06755086 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2025-01-06
Last updated
2025-01-01

Condition(s) studied

Solid Tumors

Investigational drug(s) / intervention(s)

18-FDG →

18-FDG: All study participants will undergo one 18F-FDG PET/ CT scan.

Study summary

The objective of the study is to construct a noninvasive approach using 124I-labeled monoclonal antibody radiotracer to detect the Thomsen-Friedenreich antigen (TF-antigen, CD176) expression of tumor lesions in patients with solid tumors and to identify patients benefiting from TF-antigen targeting treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 and ≤ 75 years, male or female; 2. ECOG performance status score of 0 or 1; 3. Expected survival time ≥ 6 months; 4. At least one measurable tumor lesion exists according to RECIST 1.1 criteria (e.g., lung cancer, gastric cancer, colorectal cancer, breast cancer, pancreatic cancer, hepatocellular carcinoma). The lesion must be eligible for biopsy within one month before or after a PET scan, and the patient must be able to provide 2-3 tissue slices of the lesion; 5. Subjects must fully understand and voluntarily agree to participate in the study and sign an informed consent form. Exclusion Criteria: 1. Pregnant or breastfeeding women, or women planning to become pregnant during the study period or within three months after drug administration, as well as individuals donating sperm or eggs; 2. Individuals known or suspected to be allergic to the investigational drug or any of its components; 3. Individuals with significantly impaired liver or kidney function; 4. Individuals unable to comply with PET examinations or those with conditions such as claustrophobia that prevent them from undergoing PET scans.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Cancer Hospital Beijing Beijing Municipality

More Peking University Cancer Hospital & Institute trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06755086 on ClinicalTrials.gov ↗ ← All trials in China